Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin and beta-methyldigoxin
- PMID: 598412
- DOI: 10.1007/BF00562456
Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin and beta-methyldigoxin
Abstract
Five healthy volunteers received digoxin 0.4 mg or beta-methyldigoxin 0.4 mg i.v., daily for 14 days, in a randomized cross-over arrangement. By monitoring minimal plasma concentrations during multiple dosing, it was found that the steady state pharmacokinetics of digoxin and beta-methyldigoxin could be estimated even better by a one-compartment than by a two-compartment model. The following mean parameters were calculated: the half life of digoxin of 1.54 +/- 0.31 days was significantly shorter than the half life of 2.29 +/- 0.34 days for beta-methyldigoxin. The distribution volume of 807 +/- 187 liters for digoxin was not significantly larger than the 735 +/- 227 liters for beta-methyldigoxin. Renal digoxin clearance of 191 +/- 25 ml/min was significantly higher than both the renal clearance of beta-methyldigoxin of 111 +/- 23 ml/min and also the creatinine clearance, which indicates tubular secretion of digoxin. There was a 2.8-fold accumulation of beta-methyldigoxin injected once a day, which was significantly higher than the 1.80-fold accumulation of digoxin.
Similar articles
-
[Pharmacokinetics of beta-methyldigoxin and beta-acetyldigoxin in patients with cirrhosis of the liver (author's transl)].Wien Klin Wochenschr. 1981 Oct 2;93(18):572-6. Wien Klin Wochenschr. 1981. PMID: 7303703 Clinical Trial. German.
-
Pharmacokinetics of beta-methyldigoxin in healthy humans I: intravenous studies.J Pharm Sci. 1977 Feb;66(2):242-53. doi: 10.1002/jps.2600660228. J Pharm Sci. 1977. PMID: 839422
-
Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.J Pharm Sci. 1977 Mar;66(3):314-25. doi: 10.1002/jps.2600660304. J Pharm Sci. 1977. PMID: 845795
-
[No advantages of acetyldigoxin and methyldigoxin compared to digoxin].Dtsch Med Wochenschr. 1982 May 28;107(21):831-3. doi: 10.1055/s-2008-1070029. Dtsch Med Wochenschr. 1982. PMID: 7042270 Review. German. No abstract available.
-
[Beta-methyldigoxin and hepatic cirrhosis. Parallel study of the metabolism of digoxin in normal subjects and those with hepatic insufficiency].Minerva Dietol Gastroenterol. 1981 Oct-Dec;27(4):513-20. Minerva Dietol Gastroenterol. 1981. PMID: 7038542 Review. Italian. No abstract available.
Cited by
-
On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.Eur J Clin Pharmacol. 1983;25(3):369-73. doi: 10.1007/BF01037950. Eur J Clin Pharmacol. 1983. PMID: 6628525
-
Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results from a phase I, multiple-dose, double-blind, randomised, placebo-controlled, crossover trial.Clin Drug Investig. 2014 May;34(5):327-34. doi: 10.1007/s40261-014-0180-7. Clin Drug Investig. 2014. PMID: 24634110 Clinical Trial.
-
Evidence of nonlinearity in digoxin pharmacokinetics.J Pharmacokinet Biopharm. 1981 Apr;9(2):147-66. doi: 10.1007/BF01068079. J Pharmacokinet Biopharm. 1981. PMID: 7277206
-
On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.J Pharmacokinet Biopharm. 1986 Aug;14(4):357-64. doi: 10.1007/BF01059196. J Pharmacokinet Biopharm. 1986. PMID: 3772737
-
Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution.Eur J Clin Pharmacol. 1980 Nov;18(5):433-41. doi: 10.1007/BF00636799. Eur J Clin Pharmacol. 1980. PMID: 7439268
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources